Tuesday, February 7, 2023

561.316.3330

Biotechnology News Magazine

Center for Medicare Services Established National Pricing of VENDAJETM in All MAC regions

Latest Posts

Nectin Therapeutics to Collaborate with Merck on Clinical Trial of Anti-PVR Antibody NTX1088 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Locally Advanced and...

NTX1088 is a First-in-Class and highly potent monoclonal antibody directed against PVR (CD155), a transmembrane protein expressed on cancer cells and associated with resistance to PD1 and PDL1 immune checkpoint inhibitors.

TransCure bioServices Offers BioVolume 3D Imaging for Insightful Preclinical Oncology Research

BioVolume reconstructs tumors from 3D, RGB, and thermal imaging. The solution is non-invasive, using a machine learning algorithm to automatically calculate subcutaneous tumor length, height, and width.

CLINUVEL Drug Significantly Reduces UV Skin Damage

“Today’s results build upon the decades of research CLINUVEL has conducted into the use of afamelanotide to protect skin from light, with the first evidence that a single dose of the drug has a photoprotective effect in healthy volunteers. These data add to our regulatory dossier for XP while further developing our specialised healthcare products for wider populations at highest risk of UV-induced damage and skin cancer,” Dr Bilbao said.

Deciphex Completes Validation Activities Enabling Veterinary Consultant Pathologists to Perform CLP Peer Review Digitally Using Patholytix

GLP and non-GLP studies can now be digitally peer reviewed by consultant pathologists for CROs and Pharma companies leading to faster study review and reduced backlogs with Drug candidates brought to clinical trials sooner advises Deciphex.

BioStem Technologies Inc. (OTCQB: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics for advanced wound care, announced that the Center for Medicare Services (“CMS”) has established national pricing of VENDAJETM in all Medicare Administrative Contractors (MAC) regions, effective January 1, 2023.

Jason Matuszewski, Chief Executive Officer of BioStem Technologies Inc. said, “This is a big accomplishment for BioStem Technologies and an added benefit for Medicare patients across the United States. Prior to this milestone, reimbursement for VENDAJETM was restricted to certain MAC regions. Now we will be able to offer VENDAJETM to all Medicare providers across the United States. VENDAJETM allografts now offers healthcare providers and their Medicare beneficiary patients a proven effective, reimbursable treatment option for lower extremity non-healing wounds. This accelerates our momentum as we expand availability of VENDAJETM to even more patients, thereby increasing adoption and creating better patient outcomes.”

On January 1, 2023 CMS established and published the national pricing data for reimbursement based on the Average Sales Price (“ASP”) of VENDAJETM. Establishing national pricing for VENDAJETM enables BioStem to offer its product to all Medicare providers across the U.S., streamlines the reimbursement process and potentially accelerates reimbursement payments in all MAC regions.

Andrew Van Vurst, Chief Operating Officer of BioStem Technologies Inc. added, “This is a significant milestone in VENDAJE’s commercial launch and will provide a streamlined and efficient reimbursement process. To date, we are encouraged by the payer coverage and are dedicated to facilitating patient access to VENDAJETM. This step further accelerates the successful roll out of VENDAJETM, the only allograft available that leverages BioStem’s proprietary BioREtain processing technology.”

Available by prescription through a health care provider in all 50 states, VENDAJE offers patients who are experiencing non-healing lower extremity wounds an advanced treatment option that acts as a protective barrier or covering to provide an optimal environment for wound healing and closure.

Patients interested in learning more about VENDAJE allografts can visit www.vendaje.biostemtechnologies.com or speak with their local provider.

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine